|
| Press Releases |
|
 |
|
| Wednesday, April 9, 2025 |
|
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
| SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
| Tuesday, April 16, 2024 |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, June 12, 2023 |
|
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, May 22, 2023 |
|
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, December 19, 2022 |
|
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 4, 2022 |
|
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, July 8, 2022 |
|
|
SinoMab Received the Highest Subsidy from HKSTP |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
As Geekplus approaches the unlocking, the major cornerstone investors such as Xiongan Fund commit to holding their shares
Jan 5, 2026 09:46 HKT/SGT
|
|
|
Hong Kong Tech Exhibits Immense Potential at CES 2026 with 61 Tech Companies Ready for Global Markets, Largest-ever Hong Kong Tech Pavilion features 3 Innovation Award-winning game-changers showcasing immense potential to scale
Jan 4, 2026 12:03 HKT/SGT
|
|
|
Ev Dynamics Enters into Strategic Cooperation with Xinjiang Huiyi New Energy, Jointly Building an Efficient, Green and Intelligent New Energy Bulk Logistics Transportation System
Jan 2, 2026 10:27 HKT/SGT
|
|
|
EB5 United Surpasses 700+ I-526E Approvals, Reinforcing Leadership in Rural EB-5 post-RIA 
Jan 1, 2026 13:00 HKT/SGT
|
|
|
Iluvatar CoreX's Hong Kong IPO: Hardcore Breakthrough Battle of China's General-Purpose GPU 'Leader'
Dec 31, 2025 12:09 HKT/SGT
|
|
|
Radisson Reflects on a Successful 2025 and Provides 2026 Outlook
Dec 30, 2025 23:00 HKT/SGT
|
|
|
CBL International Facilitates Xiaomo Port's First LNG Bunkering for BYD in Shenzhen
Dec 30, 2025 18:15 HKT/SGT
|
|
|
USAS Building System Listed on the Hong Kong Stock Exchange: A Top-Three Industrial Prefabricated Steel Structure Solution Provider Enters a New Phase in the Capital Markets
Dec 30, 2025 10:13 HKT/SGT
|
|
|
Autonomous Driving Enters the Core Value Realization Phase: What Anchors CIDI's Valuation?
Dec 29, 2025 17:20 HKT/SGT
|
|
|
USAS Building System Advances Toward Hong Kong Listing: A Top-Three Industrial Prefabricated Steel Structure Solution Provider, with an Emerging Overseas Growth Curve
Dec 29, 2025 14:48 HKT/SGT
|
|
|
Taxinexo Advances Large-Scale Commercial Deployment of Level 4 Autonomous Vehicles Across the United States
Dec 26, 2025 22:00 HKT/SGT
|
|
|
Honda Newly Launches "Discover Honda" Content Curation Media Platform
Dec 26, 2025 17:34 JST
|
|
|
Mazda Selected for A List in CDP Water Security for the First Time
Dec 26, 2025 17:19 JST
|
|
|
Fujitsu Develops Fujitsu Kozuchi Physical AI 1.0 for Seamless Integration of Physical and Agentic AI
Dec 26, 2025 14:04 JST
|
|
|
Establishment of DOCOMO Innovation Fund IV, a Corporate Venture Investment Fund
Dec 26, 2025 13:53 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
